Tumor-treating pharmaceutical composition
Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
1. A method for treating a tumor, comprising administering a therapeutically effective amount of lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide to a patient in need thereof, wherein the tumor is breast cancer, a thyroid cancer, hepatocellular carcinoma, colorectal cancer, renal cell carcinoma, head and neck cancer, endometrial cancer, or melanoma.
2. The method according to claim 1 , wherein the lenvatinib or the pharmaceutically acceptable salt thereof is lenvatinib mesylate.
3. The method according to claim 1 , wherein the lenvatinib or the pharmaceutically acceptable salt thereof, and the (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide are administered simultaneously, separately, continuously, or at time intervals.
4. The method according to claim 1 , wherein the tumor is breast cancer.
5. The method according to claim 1 , wherein the tumor is a thyroid cancer.
6. The method according to claim 5 , wherein the thyroid cancer is anaplastic thyroid cancer.
7. The method according to claim 1 , wherein the tumor is hepatocellular carcinoma.
8. The method according to claim 1 , wherein the tumor is colorectal cancer.
9. The method according to claim 1 , wherein the tumor is renal cell carcinoma.
10. The method according to claim 1 , wherein the tumor is head and neck cancer.
11. The method according to claim 1 , wherein the tumor is endometrial cancer.
12. The method according to claim 1 , wherein the tumor is melanoma.
13. The method according to claim 4 , wherein the lenvatinib or the pharmaceutically acceptable salt thereof is lenvatinib mesylate.
14. The method according to claim 5 , wherein the lenvatinib or the pharmaceutically acceptable salt thereof is lenvatinib mesylate.
15. The method according to claim 6 , wherein the lenvatinib or the pharmaceutically acceptable salt thereof is lenvatinib mesylate.
16. The method according to claim 7 , wherein the lenvatinib or the pharmaceutically acceptable salt thereof is lenvatinib mesylate.
17. The method according to claim 8 , wherein the lenvatinib or the pharmaceutically acceptable salt thereof is lenvatinib mesylate.
18. The method according to claim 9 , wherein the lenvatinib or the pharmaceutically acceptable salt thereof is lenvatinib mesylate.
19. The method according to claim 10 , wherein the lenvatinib or the pharmaceutically acceptable salt thereof is lenvatinib mesylate.
20. The method according to claim 11 , wherein the lenvatinib or the pharmaceutically acceptable salt thereof is lenvatinib mesylate.
21. The method according to claim 12 , wherein the lenvatinib or the pharmaceutically acceptable salt thereof is lenvatinib mesylate.